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Background: Chronic obstructive pulmonary disease (COPD) and asthma may overlap and 
converge in older people (overlap syndrome). It was hypothesized that patients with overlap 
syndrome may have different clinical characteristics such as sputum eosinophilia, and better 
responsiveness to treatment with inhaled corticosteroid (ICS).
Methods: Sixty-three patients with stable COPD (forced expiratory volume in 1 second 
[FEV1] #80%) underwent pulmonary function tests, including reversibility of airflow l  imitation, 
arterial blood gas analysis, analysis of inflammatory cells in induced sputum, and chest high-
resolution computed tomography. The inclusion criteria for COPD patients with asthmatic 
symptoms included having asthmatic symptoms such as episodic breathlessness, wheezing, 
cough, and chest tightness worsening at night or in the early morning (COPD with asthma 
group). The clinical features of COPD patients with asthmatic symptoms were compared with 
those of COPD patients without asthmatic symptoms (COPD without asthma group).
Results: The increases in FEV1 in response to treatment with ICS were significantly higher 
in the COPD with asthma group. The peripheral eosinophil counts and sputum eosinophil 
counts were significantly higher. The prevalence of patients with bronchial wall thickening on 
chest high-resolution computed tomography was significantly higher. A significant correlation 
was observed between the increases in FEV1 in response to treatment with ICS and sputum 
eosinophil counts, and between the increases in FEV1 in response to treatment with ICS and the 
grade of bronchial wall thickening. Receiver operating characteristic curve analysis revealed 
82.4% sensitivity and 84.8% specificity of sputum eosinophil count for detecting COPD with 
asthma, using 2.5% as the cutoff value.
Conclusion: COPD patients with asthmatic symptoms had some clinical features. ICS should 
be considered earlier as a potential treatment in such patients. High sputum eosinophil counts 
and bronchial wall thickening on chest high-resolution computed tomography might therefore 
be a good predictor of response to ICS.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by 
  airflow limitation that is not fully reversible according to the Global Initiative for 
Chronic Obstructive Lung Disease guidelines.1 Irreversible airflow limitation is defined 
as the proportion of forced vital capacity (FVC) in 1 second, ie, forced expiratory 
volume in 1 second (FEV1)/FVC ratio, being ,70% after inhalation of β2-agonist. 
However, COPD is not a simple homogenous disease clinically defined only as 
irreversible airflow limitation. For example, COPD has some morphological pheno-
types on chest high-resolution computed tomography (HRCT), and each   phenotype 
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is associated with clinical characteristics and   different 
responsiveness to bronchodilators.2,3 Moreover, COPD 
can coexist with asthma which may also cause   irreversible 
  airflow limitation,4 although COPD and asthma are two quite 
different and independent diseases. Asthma may be a risk 
factor for the development of COPD.5 In particular, COPD 
and asthma may overlap and converge in older people.6,7 
However, the potential for overlap of the individual obstruc-
tive airway d  isease syndromes, including COPD and asthma, 
has received less attention.8
For this study, it was hypothesized that COPD patients 
with asthmatic symptoms may have different clinical features 
than COPD patients without asthmatic symptoms. The aim of 
this study was to clarify the features of COPD patients with 
asthmatic symptoms, and these findings may therefore play 
a role in developing the optimal strategy for the management 
of COPD with asthmatic symptoms.
Methods
Subjects
A total of 63 patients with stable COPD, who showed 
FEV1/FVC ,70% and FEV1 , 80% of the predicted value 
after inhalation of a β2-agonist (moderate to very severe 
COPD) and were seen at the outpatient clinic of Shinshu 
University Hospital (Matsumoto, Japan) from February 
2007 to July 2009, were recruited for this study. The 
diagnosis of COPD was based on the clinical history and 
symptoms, including dyspnea on exertion and pulmonary 
function characterized by irreversible airflow limitation 
(FEV1/FVC ,70% after inhalation of a β2-agonist) 
in accordance with the Global Initiative for Chronic 
O  bstructive Lung Disease guidelines.1 All subjects had 
smoking-related COPD without α1-antitrypsin deficiency, 
and had a smoking history of more than 30 pack years. All 
patients with COPD without asthmatic symptoms had no 
history of asthma or asthmatic symptoms (COPD without 
asthma group). All patients with COPD with asthmatic 
symptoms had experienced asthmatic symptoms such 
as episodic breathlessness, wheezing, cough, and chest 
tightness worsening at night or in the early morning (COPD 
with asthma group). The exclusion criteria included the 
presence of a respiratory tract infection or exacerbation 
of COPD and/or asthma during the preceding 3 months. 
In total, 46 patients were in the COPD without asthma 
group and 17 patients were in the COPD with asthma group. 
Most of the patients used short-acting β2-agonists as needed 
to relieve dyspnea two to three times per week, but did 
not use them on the day that the pulmonary function tests 
were performed.
The study was approved by the institutional research 
ethics committee of Shinshu University School of Medicine 
(Matsumoto, Japan), and all patients gave written informed 
consent to participate.
Protocol
Information was obtained from each patient on the history 
of the current illness including complications and history of 
smoking, physical and laboratory examinations, pulmonary 
function tests including reversibility of airflow limitation by 
β2-agonist (20 µg of inhaled procaterol hydrochloride), arterial 
blood gas analysis, analysis of inflammatory cells in induced 
sputum, and the findings on chest HRCT. The patients were 
treated with inhaled corticosteroid (ICS; 400 µg/day of inhaled 
fluticasone propionate) for 2–3 months. Pulmonary measure-
ments were again obtained by spirometry after treatment.
Pulmonary function tests
Spirometry and measurements of the diffusing capacity for 
carbon monoxide (DLCO) were performed using a pulmonary 
function testing system (Chestac-55V; Chest Co, Ltd, Tokyo, 
Japan). FEV1 was measured before and 20 minutes after inha-
lation of β2-agonist (20 µg of procaterol h  ydrochloride) by 
aerosol (metered-dose inhaler) with a spacer (Meptin®; Otsuka 
Pharmaceutical, Tokushima, Japan) to evaluate the revers-
ibility of airflow limitation. The functional residual capacity 
was measured using a body box (MedGraphics model 1085; 
Medical Graphics Corp, Minneapolis, MN), after which the 
subjects immediately inspired to total lung capacity and expired 
maximally to residual volume, thus allowing calculation of 
lung volume and residual volume/total lung capacity. The 
pulmonary function tests were performed by two special tech-
nicians according to the American Thoracic Society criteria. 
Two or three tests were repeated to guarantee repeatability.
Sputum collection and analysis
Sputum induced by the inhalation of hypertonic saline was 
collected as described previously.9 Briefly, all subjects inhaled 
a β2-agonist and 3.5% hypertonic saline nebulized with an 
ultrasonic nebulizer (NE-V10B; Omron C  orporation, Tokyo, 
Japan). The nebulization was continued for at least 10 minutes 
and stopped after 15 minutes or earlier if a $2 mL sputum 
sample of good quality was obtained. The collected sputum 
was then separated from contaminating saliva by macroscopic 
examination, and any mucus plugs were removed from the 
dish to a sterile plastic container, after which the volume 
of the sample was determined. The sample was incubated 
with an equal volume of  Hank’s balanced salt solution 
containing 1 mM dithiothreitol (Sigma-Aldrich Company 
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Ltd, Poole, United Kingdom) at 37°C for 15 minutes. The 
residual mucous was removed and the eluent was used to 
obtain total and differential cell counts. The total cell count, 
except that of squamous cells, was determined with a stan-
dard hemocytometer (Fuchs Rosenthal; Erma, Tokyo, Japan), 
normalized for weight and expressed as cells 105/g wet 
weight of sputum. Cell smears were prepared with a centri-
fuge (Autosmear™; Sakura Keishi Kabushiki Kaisha, Tokyo, 
Japan) and stained with May-Grünwald-Giemsa (Merck, 
Darmstadt, Germany) for differential cell counting. The slides 
were coated and then 500 cells were counted to determine 
the differential leukocyte count.
HrCT protocol and evaluation  
of the degree of emphysema  
and bronchial wall thickening (BWT)
A helical CT scanner (LightSpeed VCT; GE Healthcare, 
Waukesha, WI) was used for conventional contiguous scanning 
with a slice thickness of 10 mm to screen for chest abnormalities 
followed by HRCT scanning at full inspiration (at total lung 
capacity level) with 1 mm collimation (120 kVp, 200 mA, 
pitch 1.0). Four 1 mm thick slices were obtained at three 
anatomical levels at full inspiration: near the superior margin 
of the aortic arch, at the level of the carina, and at the level of 
the orifice of the inferior pulmonary veins. The low attenuation 
area (LAA) was visually scored in each bilateral lung field 
according to the method of Goddard et al.10 Total scores were 
calculated and the severity of emphysema was graded as: score 
0, LAA , 5%; score 1, 5% # LAA , 25%; score 2, 25% # 
LAA , 50%; score 3, 50% # LAA , 75%; and score 4, LAA 
$ 75%. The severity of emphysema was graded in accordance 
with the sum of the scores for six dimensions: grade 0, total 
score = 0; grade 1, total score = 1–6; grade 2, total score = 7–12; 
grade 3, total score = 13–18; and grade 4, total score = 19–24. 
The patients were classified according to the visual HRCT 
findings as: absence of emphysema phenotype, which showed 
little emphysema and at least LAA grade 1, and emphysema 
phenotype, which showed apparent emphysema (at least 
grade 2). BWT in all lung fields was graded visually as reported 
previously:11,12 grade 0, none; grade 1, ,50% adjacent pulmonary 
artery diameter; and grade 2, $50% adjacent pulmonary artery 
diameter. The patients without BWT showed BWT of grade 0, and 
patients with BWT showed BWT of more than grade 1. HRCT 
images were analyzed independently by two pulmonologists 
with no knowledge of the patients’ clinical status.
Statistical analysis
The values shown in the text and tables are the mean ± s  tandard 
error of the mean. The data distribution of the variables in 
the groups was first assessed with Bartlett’s test. Data for the 
variables that showed a normal distribution were compared 
using the parametric Student’s t-test. Data for the variables 
that did not show a normal distribution were compared 
using the nonparametric Mann–Whitney U-test. Simple 
c  orrelations between variables were examined by calculat-
ing Pearson’s product correlation coefficient. Cutoff values 
of the sputum eosinophil count for detecting COPD with 
asthma were calculated from receiver operator characteristic 
curve analysis, with sensitivity and specificity determined in 
each case. All statistical analyses were performed with the 
use of a Windows®-compatible software program (StatFlex 
version 5.0; Artech Ltd, Osaka, Japan). A P value of less 
than 0.05 was considered to be significant in all statistical 
analyses.
Results
Clinical characteristics of each group
There were no significant differences in age, gender, body 
mass index, Brinkman index, history of sinusitis, or history 
of noxious particles or gases other than tobacco between 
the two groups (Table 1). The prevalence of history of 
allergic rhinitis was significantly higher in the COPD with 
asthma group. A laboratory analysis showed no cases of 
α1-antitrypsin deficiency, and no significant difference 
was observed in the serum α1-antitrypsin and serum total 
immunoglobulin E levels between the two groups. The 
peripheral eosinophil counts were significantly higher in 
the COPD with asthma group. Seven of the COPD patients 
Table 1 Clinical characteristics and laboratory data in patients with 
chronic obstructive pulmonary disease with and without asthma
COPD without  
asthma 
(n = 46)
COPD with   
asthma 
(n = 17)
Age (years) 71 ± 1 73 ± 1
gender (female/male) 6/40 0/17
Body mass index (kg/m2) 20.6 ± 0.5 21.3 ± 0.8
History of smoking (pack years) 60.8 ± 4.1 55.5 ± 5.4
History of sinusitis (n [%]) 9 (19.7%) 5 (29.4%)
History of allergic rhinitis 4 (8.7%) 5 (29.4%)*
History of noxious particles or  
gases other than tobacco (n [%])
18 (39.1%) 7 (41.2%)
α1-antitrypsin (mg/dL) 150.0 ± 8.6 136.4 ± 4.7
Serum total immunoglobulin E  
(IU/mL)‡
249.0 ± 99.4 693.1 ± 309.4
Peripheral eosinophil count (/mm3) 207.9 ± 31.7 407.5 ± 81.8*
Notes: Values are the number (%) or the mean ± standard error of the mean; 
*P , 0.05 versus chronic obstructive pulmonary disease without asthma; ‡normal 
range is ,400 IU/mL.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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with asthmatic symptoms (41.2%) had a history of expo-
sure to noxious particles or gases other than tobacco; three 
patients (17.6%) to asbestos and four patients (23.5%) to 
agrochemical compounds. Eighteen of the COPD patients 
without asthmatic symptoms (39.1%) had a history of 
exposure to noxious particles or gases other than tobacco; 
eight patients (17.4%) to asbestos and ten patients (21.7%) 
to agrochemical compounds.
Pulmonary function tests  
and inflammatory cell analysis  
of induced sputum
There were no significant differences in the vital capacity, 
FEV1, or FEV1/FVC (Table 2). There were no significant 
differences in lung hyperinflation expressed by increased 
residual volume and total lung capacity between the two 
groups. DLCO was significantly higher in the COPD with 
asthma group. An arterial blood gas analysis showed no 
significant differences between the two groups.
There was no significant difference in the increases in 
FEV1 in response to β2-agonist between the two groups 
(Table 3). The increases in FEV1 in response to treatment 
with ICS were significantly higher in the COPD with asthma 
group. Twelve patients in the COPD without asthma group 
(26.1%) and eleven patients in the COPD with asthma 
group (64.7%) showed a reversibility of airflow limita-
tion, which was defined as an increase in FEV1 of .12% 
and 200 mL from baseline values, in response to treatment 
with ICS for 2–3 months, and none of the patients showed 
FEV1/FVC $ 70% following the treatment with ICS.
There was no significant difference in the total cell counts 
in induced sputum. However, the eosinophil counts in induced 
sputum were significantly higher in the COPD with asthma 
group. Figure 1 shows the relationship between the increases 
in FEV1 in response to treatment with ICS and sputum eosino-
phil counts. A significant correlation was found (r = 0.42, 
P = 0.0006). Receiver operator characteristic curve analysis 
was performed to determine the sputum eosinophil count for 
detecting COPD with asthma. The sensitivity and specific-
ity of the sputum eosinophil count for detecting COPD with 
asthma were 82.4% and 84.8%, respectively, when the cutoff 
value for the sputum eosinophil count was 2.5%.
Table 2 Pulmonary function in patients with chronic obstructive 
pulmonary disease with and without asthma
COPD without asthma 
(n = 46)
COPD with asthma 
(n = 17)
VC (% pred)   92.3 ± 3.1   96.6 ± 3.6
FEV1 (% pred)   47.5 ± 2.8   51.3 ± 3.5
FEV1/FVC (%)   46.1 ± 1.7   50.9 ± 2.9
TLC (% pred) 132.0 ± 3.3 120.6 ± 4.9
rV (% pred) 228.5 ± 9.9 192.8 ± 13.9
rV/TLC (%)   57.0 ± 1.5   51.7 ± 1.9
DLCO (% pred)   56.2 ± 3.5   72.2 ± 5.4*
PaO2 (Torr)   67.7 ± 1.8   75.9 ± 2.7
PaCO2 (Torr)   42.0 ± 0.8   40.4 ± 1.0
Notes: Values are the number (%) or the mean ± standard error of the mean; 
*P , 0.05 versus chronic obstructive pulmonary disease without asthma.
Abbreviations: COPD, chronic obstructive pulmonary disease; DLCO, diffusing 
capacity  for  carbon  monoxide;  FEV1,  forced  expiratory  volume  in  1  second; 
FVC, forced vital capacity; PaO2, partial pressure of arterial oxygen; PaCO2, partial 
pressure of arterial carbon dioxide; rV, residual volume; TLC, total lung capacity; 
VC, vital capacity; % pred, percent predicted.
Table 3 responses to β2-agonist and inhaled corticosteroid, and 
cell analysis in induced sputum
COPD without  
asthma 
(n = 46)
COPD with  
asthma 
(n = 17)
response to β2-agonist
 Δ FEV1 (mL) 123.7 ± 17.6 186.5 ± 29.8
  % change in FEV1 (%)   11.4 ± 2.0   17.2 ± 3.8
response to treatment with inhaled corticosteroid
 Δ FEV1 (mL) 120.2 ± 21.5 372.4 ± 58.0**
  % change in FEV1 (%)   12.8 ± 2.2   32.4 ± 6.2**
Sputum cell differentiation
  Total cell (×105/g)   87.5 ± 24.8 109.3 ± 25.4
  Macrophage (%)   11.6 ± 1.8   9.9 ± 2.2
  Lymphocyte (%)   3.8 ± 0.5   3.8 ± 0.7
  neutrophil (%)   82.6 ± 2.1   74.0 ± 4.4
  Eosinophil (%)   2.0 ± 0.5   12.3 ± 3.3**
Notes: Values are the number (%) or the mean ± standard error of the mean; 
**P  ,  0.01  versus  chronic  obstructive  pulmonary  disease  without  asthma. 
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  FEV1,  forced 
expiratory volume in 1 second; ΔFEV1, increases in forced expiratory volume in 
1 second.
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Figure 1 relationship between response to treatment of inhaled corticosteroid and 
sputum eosinophils counts.
Abbreviations: COPD, chronic obstructive pulmonary disease; ΔFEV1, increases in 
forced expiratory volume in 1 second.
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Degree of emphysema and BWT 
according to the findings of HRCT
No significant difference was found in the score of LAA 
between the two groups (Table 4). Thirty-eight of 46 patients 
in the COPD without asthma group and 13 of 17 patients in 
the COPD with asthma group were classified into the emphy-
sema phenotype. The remaining eight patients in the COPD 
without asthma group and four patients in the COPD with 
asthma group were classified into the absence of emphysema 
phenotype. The prevalence of patients with BWT was signifi-
cantly higher in the COPD with asthma group. Furthermore, 
the prevalence of patients with BWT was significantly higher 
in the COPD with asthma group than in the COPD without 
asthma group only in the patients with the emphysema 
  phenotype. A significant correlation was observed between 
the increases in FEV1 in response to treatment with ICS and 
the grade of BWT (r = 0.41, P = 0.0007).
Discussion
The current study found the increases in FEV1 in response 
to treatment with ICS were significantly higher in the COPD 
with asthma group, although no significant difference was 
found in the increases in FEV1 in response to β2-agonist 
between the two groups. Both the peripheral eosinophil 
counts and sputum eosinophil counts were significantly 
higher in the COPD with asthma group. Chest HRCT showed 
that the prevalence of patients with BWT was significantly 
higher in the COPD with asthma group. A significant correla-
tion was observed between the increases in FEV1 in response 
to treatment with ICS and sputum eosinophil counts, and 
between the increases in FEV1 in response to treatment with 
ICS and the grade of BWT. Receiver operator characteristic 
curve analysis revealed 82.4% sensitivity and 84.8% speci-
ficity of sputum eosinophil count for detecting COPD with 
asthma, using 2.5% as the cutoff value.
The underlying chronic airway inflammation in COPD 
is very different than that in asthma. Asthma is traditionally 
characterized by an eosinophilic inflammation that affects 
all the airways but not lung parenchyma, and it is linked to 
airway hyperresponsiveness.13 However, asthmatic patients 
that smoke develop pathological features similar to COPD.14 
Some patients with COPD may demonstrate features of 
asthma, such as a mixed inflammatory pattern with increased 
eosinophils,15 and an increased sputum eosinophil count has 
been reported to be related to an improvement in FEV1 fol-
lowing treatment with ICS in COPD.16 The peripheral eosino-
phil counts and sputum eosinophil counts were significantly 
higher, and the reversibility due to a response to the treatment 
with ICS was better in the COPD with asthma group in the 
current series. These results suggest that COPD patients 
with asthmatic symptoms also had features of asthma such 
as a mixed inflammatory pattern with increased eosinophils. 
A significant correlation was observed between the increases 
in FEV1 in response to treatment with ICS and sputum eosino-
phil counts, thus suggesting that high sputum eosinophil 
counts might be a good predictor of response to ICS.
Pulmonary function testing with bronchodilators has 
been used to differentiate asthma from COPD, with COPD 
demonstrating a smaller response.17 However, some patients 
with COPD showed reversibility, which is defined as an 
increase in FEV1 of .12% and 200 mL from baseline val-
ues, in response to bronchodilators.18 The degree of revers-
ibility of airflow limitation is no longer recommended for 
diagnosis, differential diagnosis with asthma, or predicting 
the response to longer treatment with bronchodilators or 
glucocorticosteroids according to the Global Initiative for 
Chronic   Obstructive Lung Disease guidelines.1 The current 
study found no significant difference in the increases in FEV1 
in response to β2-agonist between the two groups, and this 
result was consistent with the findings of previous reports.
The major differences in airway remodeling between 
asthma and COPD are the thickening of the reticular layer 
under the basement membrane with submucosal infiltration of 
a large number of eosinophils and the proliferation of mucosal 
blood vessels found in asthma. On the contrary, it seems that 
fixed airway obstruction is the final result of structural changes 
of peripheral airways and lung parenchyma in COPD.13,19,20 
Therefore, these diseases have different pathologies of airway 
remodeling. However, it is difficult to clinically differentiate 
between COPD and asthma in some patients with irreversible 
Table 4 Chest high-resolution computed tomography findings
COPD without  
asthma 
(n = 46)
COPD with   
asthma 
(n = 17)
LAA score 17.9 ± 1.3 13.8 ± 2.3
BWT (+) (n [%]) 16 (34.8%) 11 (64.7%)*
Constitution of the phenotypes
  Emphysema phenotype 38 (82.6%) 13 (76.5%)
  BWT (-) 26 (56.5%) 4 (23.5%)*
  BWT (+) 12 (26.1%) 9 (52.9%)*
Absence of emphysema phenotype 8 (17.4%) 4 (23.5%)
  BWT (-) 4 (8.7%) 2 (11.8%)
  BWT (+) 4 (8.7%) 2 (11.8%)
Notes: Values are the number (%) or the mean ± standard error of the mean; 
*P , 0.05 versus chronic obstructive pulmonary disease without asthma.
Abbreviations: BWT (-), bronchial wall thickening of grade 0; BWT (+), bronchial 
wall thickening of more than grade 1; COPD, chronic obstructive pulmonary disease; 
LAA, low attenuation area.
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airflow limitation.13 Airway remodeling is thought to be the 
main cause of irreversible airflow limitation in older asth-
matic patients. The presence of a normal diffusing capacity 
for DLCO may be useful to differentiate asthma with airway 
remodeling from COPD. However, COPD has morphological 
phenotypes on chest HRCT and some patients with COPD 
that show normal capacity for DLCO are classified into the 
absence of emphysema phenotype.2,3 There is a possibility 
that the COPD with asthma group included asthmatic patients 
with airway remodeling in this study, because it is sometimes 
difficult to clinically differentiate such patients from COPD 
patients who are classified into the absence of emphysema 
phenotype. Nonetheless, ICS should be considered earlier as 
a potential treatment in patients who are clinically diagnosed 
to have COPD with asthmatic symptoms. While DLCO was 
significantly lower in the COPD with asthma group, this 
may be because the mean value of LAA score was lower 
in the COPD with asthma group. Alternatively, this may be 
because asthmatic patients show relatively higher values of 
DLCO because allergic inflammation may affect pulmonary 
circulation.21
HRCT used to quantify abnormalities of the airways 
due to airway remodeling in asthma, and the HRCT scan 
score is correlated with the severity of asthma and airflow 
obstruction.22–24 The absence of emphysema phenotype and 
emphysema with BWT phenotype are associated with a better 
responsiveness to treatment with ICS in COPD patients.2,3 
The prevalence of patients with BWT was significantly higher 
in the COPD with asthma group on chest HRCT in the current 
series. A significant correlation was observed between the 
increases in FEV1 in response to treatment with ICS and the 
grade of BWT. The current results were consistent with those 
of previous reports and suggest that BWT on chest HRCT 
might be a good predictor of response to ICS.
One limitation of this retrospective study is that the 
assessment of emphysema was done by a visual scoring 
method, rather than using a software-based quantification 
of emphysema. However, the reproducibility of such visual 
scoring has been demonstrated in a previous report.3 Another 
limitation is the lack of statistical power because the sample 
size was small for the absence of emphysema phenotype 
(n = 4 in the COPD with asthma group and n = 8 in the COPD 
without asthma group) which is generally lower, accounting 
for only about 22% of COPD.2,3 Another limitation of these 
findings is associated with the fact that while many statistical 
differences and correlations were observed, these results by 
themselves do not imply cause and effect.
Conclusion
COPD patients with asthmatic symptoms had some clini-
cal features such as high peripheral eosinophil counts, high 
sputum eosinophil counts, preserved diffusing capacity, high 
prevalence of BWT on chest HRCT, and better reversibility 
responsive to treatment with ICS. ICS should thus be consid-
ered earlier as a potential treatment in COPD patients with 
asthmatic symptoms. High sputum eosinophil counts and 
BWT on chest HRCT might therefore be a good predictor 
of response to ICS.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Global Initiative for Chronic Obstructive Lung Disease. Global strategy 
for the diagnosis, management, and prevention of chronic   obstructive 
pulmonary disease. Updated 2010. Available from: http://www.
goldcopd.org/Guidelines/guideline-2010-gold-report.html. Accessed 
February 7, 2012.
  2.  Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD 
phenotypes classified according to the findings of HRCT. Respir Med. 
2006;100(10):1742–1752.
  3.  Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of 
chronic obstructive pulmonary disease phenotypes classified using 
high-resolution computed tomography. Respirology. 2006;11(6): 
731–740.
  4.  Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma 
DS. Risk factors associated with the presence of irreversible airflow 
limitation and reduced transfer coefficient in patients with asthma after 
26 years of follow up. Thorax. 2003;58(4):322–327.
  5.  Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor 
for COPD in a longitudinal study. Chest. 2004;126(1):59–65.
  6.  Diaz-Guzman E, Mannino DM. Airway obstructive diseases in 
older adults: from detection to treatment. J Allergy Clin Immunol. 
2010;126(4):702–709.
  7.  Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 
2010;376(9743):803–813.
  8.  Gibson PG, Simpson JL. The overlap syndrome of asthma and 
COPD: what are its features and how important is it? Thorax. 
2009;64(8):728–735.
  9.  Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic 
protein levels in induced sputum correlate with the severity of bronchial 
asthma. Chest. 1997;112(5):1241–1247.
  10.  Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography 
in pulmonary emphysema. Clin Radiol. 1982;33(4):379–387.
  11.  Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in 
b  ronchiectasis: correlation between computed tomography features 
and pulmonary function tests. Thorax. 2000;55(3):198–204.
  12.  Copley SJ, Wells AU, Muller NL, et al. Thin-section CT in obstructive 
pulmonary disease: discriminatory value. Radiology. 2002;223(3): 
812–819.
  13.  Tzortzaki EG, Proklou A, Siafakas NM. Asthma in the elderly: can we 
distinguish it from COPD? J Allergy (Cairo). 2011;2011:843543.
  14.  Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette 
  smoking. Eur Respir J. 2004;24(5):822–833.
  15.  Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. 
Eosinophilic inflammation in the airway is related to glucocorticoid 
reversibility in patients with pulmonary emphysema. Chest. 1999; 
115(3):697–702.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
288
Kitaguchi et alInternational Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2012:7
  16.  Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and 
the short term response to inhaled mometasone in chronic obstructive 
pulmonary disease. Thorax. 2005;60(3):193–198.
  17.  Global Initiative for Asthma (GINA). Global strategy for asthma 
management and prevention. Updated 2010. Available from: 
http://www.ginasthma.org/guideline-report-2010.html. Accessed   
February 7, 2012.
  18.  Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness 
in patients with COPD. Eur Respir J. 2008;31(4):742–750.
  19.  Jeffery PK. Remodeling and inflammation of bronchi in asthma 
and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 
2004;1(3):176–183.
  20.  Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. 
Am J Respir Crit Care Med. 2001;164(10 Pt 2):S28–S38.
  21.  Collard P, Njinou B, Nejadnik B, Keyeux A, Frans A. Single breath 
diffusing capacity for carbon monoxide in stable asthma. Chest. 
1994;105(5):1426–1429.
  22.  Nakano Y, Muller NL, King GG, et al. Quantitative assessment of air-
way remodeling using high-resolution CT. Chest. 2002;122(Suppl 6): 
271S–275S.
  23.  Little SA, Sproule MW, Cowan MD, et al. High resolution computed 
tomographic assessment of airway wall thickness in chronic asthma: 
reproducibility and relationship with lung function and severity. Thorax. 
2002;57(3):247–253.
  24.  Vignola AM, Paganin F, Capieu L, et al. Airway remodelling assessed 
by sputum and high-resolution computed tomography in asthma and 
COPD. Eur Respir J. 2004;24(6):910–917.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
289
COPD patients with asthmatic symptoms